(0.11%) 5 254.11 points
(0.09%) 39 795 points
(-0.11%) 16 382 points
(2.24%) $83.17
(2.27%) $1.757
(1.34%) $2 242.30
(0.91%) $24.98
(1.34%) $921.85
(0.35%) $0.927
(0.76%) $10.85
(0.13%) $0.792
(0.14%) $92.56
Live Chart Being Loaded With Signals
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases...
Stats | |
---|---|
Today's Volume | 1.18M |
Average Volume | 2.88M |
Market Cap | 6.97B |
EPS | HKD0 ( 2022-03-22 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -13.29 |
ATR14 | HKD0.00700 (0.15%) |
Volume Correlation
InnoCare Pharma Ltd Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
InnoCare Pharma Ltd Correlation - Currency/Commodity
InnoCare Pharma Ltd Financials
Annual | 2022 |
Revenue: | HKD625.40M |
Gross Profit: | HKD482.01M (77.07 %) |
EPS: | HKD-0.590 |
Q3 | 2023 |
Revenue: | HKD159.81M |
Gross Profit: | HKD135.01M (84.48 %) |
EPS: | HKD0 |
Q2 | 2023 |
Revenue: | HKD188.16M |
Gross Profit: | HKD154.99M (82.37 %) |
EPS: | HKD-0.190 |
Q1 | 2023 |
Revenue: | HKD189.39M |
Gross Profit: | HKD146.49M (77.35 %) |
EPS: | HKD-0.0100 |
Financial Reports:
No articles found.
InnoCare Pharma Ltd
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators